# CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML

> **NCT04787263** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bambino Gesù Hospital and Research Institute** · enrollment: 32 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Diffuse Large B Cell Lymphoma
- Primary Mediastinal Lymphoma

## Interventions

- **BIOLOGICAL:** CD19-CAR_Lenti T cell

## Key facts

- **NCT ID:** NCT04787263
- **Lead sponsor:** Bambino Gesù Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-04
- **Primary completion:** 2027-03
- **Final completion:** 2038-03-03
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04787263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04787263, "CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT04787263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*